MedTrace Logo

HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer

NCT03111615 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-12-05

No results posted yet for this study

Summary

Breast Cancer is a public health issue worldwide. The time from diagnosis to treatment initiation varies from country to country and regionally within a country. Early diagnosis and prompt treatment initiation are key factors in patient survival rates.

Currently there is a rising trend, with a high percentage of patients with "Luminal" like breast cancer only undergoing adjuvant endocrine therapy.

Authors argue that tumor biology alterations after introducing very early endocrine therapy might have a prognostic and therapeutic impact and should be studied.

Conditions

  • Hormone Dependent Neoplasms
  • Breast Cancer Female

Interventions

DRUG

Aromatase Inhibitors

Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement. Venlafaxin 75 mg is to be administrated cases indicated

Sponsors & Collaborators

  • Centro Hospitalar Lisboa Ocidental

    lead OTHER_GOV

Principal Investigators

  • Vasco Fonseca, MD · CHLO Medical Oncology dpt

  • Zacharoula Sidiropoulou · CHLO Surgery dpt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-05-01
Completion
2020-05-01

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111615 on ClinicalTrials.gov